Zhejiang Medicine Co., Ltd. (SHA:600216)
China
· Delayed Price · Currency is CNY 14.70
+0.09 (0.62%)
Apr 29, 2026, 3:00 PM CST
Zhejiang Medicine Revenue
Zhejiang Medicine had revenue of 2.19B CNY in the quarter ending March 31, 2026, a decrease of -2.86%. This brings the company's revenue in the last twelve months to 8.82B, down -6.03% year-over-year. In the year 2025, Zhejiang Medicine had annual revenue of 8.88B, down -5.28%.
Revenue (ttm)
8.82B
Revenue Growth
-6.03%
P/S Ratio
1.57
Revenue / Employee
1.52M
Employees
5,815
Market Cap
13.85B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 8.88B | -494.61M | -5.28% |
| Dec 31, 2024 | 9.38B | 1.58B | 20.29% |
| Dec 31, 2023 | 7.79B | -321.66M | -3.96% |
| Dec 31, 2022 | 8.12B | -1.01B | -11.10% |
| Dec 31, 2021 | 9.13B | 1.80B | 24.60% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Zhejiang Hisun Pharmaceutical | 10.31B |
| Beijing Aosaikang Pharmaceutical | 1.83B |
| Guobang Pharma | 6.09B |
| Shenzhen Hepalink Pharmaceutical Group | 5.48B |
| Shenzhen Chipscreen Biosciences | 910.06M |
| Tibet Rhodiola Pharmaceutical Holding Co. | 2.98B |
| Shanghai Shyndec Pharmaceutical | 9.36B |
| Nanjing King-Friend Biochemical Pharmaceutical | 3.76B |